Global Hepatitis C Drugs Market 2019-2023

SKU ID : TNV- 13029934

Publishing Date : 04-Jan-2019

No. of pages : 113

PRICE
2500
4000


  • About this market
    The increasing number of voluntary licensing agreements to drive market growth. Voluntary licensing helps in improving access to essential medicines. Under the voluntary licensing agreement, patent holders license others to manufacture, import, and/or distribute their patented drugs. Voluntary licenses enable the development of generic versions of drugs, which increases the affordability and access to the patients. analysts have predicted that the hepatitis C drugs market to register a revenue of around USD 5.7 billion by 2023.
    Market Overview
    Increasing demand for direct-acting antiviral
    Direct-acting antiviral drugs have emerged as a curative option for patients with hepatitis C. These drugs act and block specific steps in the lifecycle of the HCV. They are known to target the specific nonstructural proteins of the virus that results in the disruption of viral replication. Thus, they show comparatively fewer side effects than the interferons, which were employed until the advent of direct-acting antiviral drugs.
    Side effects of available drugs
    The interferons indicated for the treatment of hepatitis C are known to be associated with harmful side effects such as excessive fatigue, headache, weight loss, alopecia, autoimmune disorders, high blood pressure, slowed growth in children, changes in vision, and malfunctioning of the lungs, liver, and pancreas. Due to these side effects, the interferon therapy is replaced by direct-acting antivirals at present.
    For the detailed list of factors that will drive and challenge the growth of the hepatitis C drugs market during the 2019-2023, view our report.
    Competitive Landscape
    The market appears to be fragmented and with the presence of several companies including Gilead and Merck the competitive environment is quite intense. Factors such as the increasing demand for direct-acting antiviral and the increasing number of voluntary licensing agreements, will provide considerable growth opportunities to hepatitis C drugs manufactures. AbbVie, Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead, and Merck are some of the major companies covered in this report.

    Frequently Asked Questions



    This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.

    • By product type
    • By End User/Applications
    • By Technology
    • By Region

    The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
    market Reports market Reports